Premenstrual tension
diseaseOn this page
Also known as PMSpremenstrual syndrome
Summary
Premenstrual tension (MONDO:0004169) is a disease with 1 GWAS associations across 3 studies and 140 clinical trials. Top therapeutic interventions include fluoxetine, ethinyl estradiol, and levonorgestrel. A subtype of menstrual disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- GWAS associations: 1
- Clinical trials: 140
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | premenstrual tension |
| Mondo ID | MONDO:0004169 |
| MeSH | D011293 |
| DOID | DOID:727 |
| UMLS | C0376356 |
| MedGen | 87683 |
| Is cancer (heuristic) | no |
Also known as: PMS · premenstrual syndrome
Data availability: 1 GWAS association (3 studies).
Disease family
An umbrella term covering 1 Mondo subtype.
Classification path: disease › human disease › disease by body system or component › reproductive system disorder › female reproductive system disorder › menstrual disorder › premenstrual tension
Related subtypes (2): amenorrhea, dysmenorrhea
Subtypes (1): premenstrual dysphoric disorder
Genetics & variants
GWAS landscape
1 GWAS associations across 3 studies. Top hits map to 0 distinct genes (as reported by GWAS).
Top associations by p-value
| rsID | p-value | Gene | Risk allele | Odds ratio |
|---|---|---|---|---|
| rs145939879 | 4e-09 | RPL24P9 - MTND6P12 | ? |
Top studies (by case count)
| Study | Lead author | Year | Cases | Controls | Title |
|---|---|---|---|---|---|
| GCST90651368 | Liu TY | 2025 | 540 | 103,376 | Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population. |
| GCST90482288 | Verma A | 2024 | 328 | 32,341 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90436526 | Zhou W | 2018 | 159 | 377,857 | Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies. |
Variant details and genetic-evidence tiers
Tier distribution (top 50 variants)
| Tier | Variants |
|---|---|
| Tier 1: coding | 0 |
| Tier 2: splice/UTR | 0 |
| Tier 3: regulatory | 0 |
| Tier 4: intronic/intergenic | 1 |
MAF distribution
| Bucket | Variants |
|---|---|
| common (>=0.05) | 0 |
| low_freq (0.01-0.05) | 0 |
| rare (<0.01) | 0 |
| unknown | 1 |
Functional consequences
| Consequence | Count |
|---|---|
| intron_variant | 1 |
Top variants
| rsID | Chr | Pos | Alleles | MAF | Consequence | Gene | p-value | Tier |
|---|---|---|---|---|---|---|---|---|
| rs145939879 | X | 4374669 | C>T | intron_variant | RPL24P9 - MTND6P12 | 4e-09 | Tier 4: intronic/intergenic |
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
0 approved, 2 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Estrone | Phase 3 (in late-stage trials) |
| Nux Vomica Extract | Phase 3 (in late-stage trials) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Drospirenone, Ethinyl Estradiol, Marvelon, Ulipristal Acetate.
Clinical trials & evidence
Clinical trials
Clinical trials: 140.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 108 |
| PHASE3 | 11 |
| PHASE2 | 8 |
| PHASE4 | 7 |
| PHASE1 | 3 |
| PHASE2/PHASE3 | 1 |
| PHASE1/PHASE2 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00318773 | PHASE4 | COMPLETED | Short-Term Versus Long-Term Treatment for Severe Premenstrual Syndrome (PMS) |
| NCT00516113 | PHASE4 | COMPLETED | A Placebo-Controlled Study to Investigate the Onset of Action of Paroxetine in Premenstrual Dysphoria |
| NCT00523705 | PHASE4 | TERMINATED | Escitalopram for Premenstrual Syndrome (PMS) in Teens: A Pilot Study |
| NCT00611923 | PHASE4 | COMPLETED | Effectiveness of Flutamide in Treating Women With Premenstrual Dysphoric Disorder |
| NCT00678574 | PHASE4 | COMPLETED | The Role of GABA and Neurosteroids in Premenstrual Dysphoric Disorder |
| NCT01482338 | PHASE4 | COMPLETED | Premenstrual Symptoms Treatment Comparing Between Oral Contraceptives Containing Desogestrel and Drospirenone |
| NCT04123483 | PHASE4 | WITHDRAWN | EnBrace HR for PMS With Prominent Mood Symptoms or Menstrual Related Mood Disorders |
| NCT00128934 | PHASE3 | COMPLETED | Study Evaluating Combination of Levonorgestrel (LNG) and Ethinyl Estradiol (EE) in Premenstrual Dysphoric Disorder |
| NCT00161681 | PHASE3 | COMPLETED | Study Evaluating Levonorgestrel/Ethinyl Estradiol (LNG/EE) in PMS |
| NCT00195559 | PHASE3 | COMPLETED | Study Evaluating Combination of Levonorgestrel and Ethinyl Estradiol in Pre-Menstrual Dysphoric Disorder |
| NCT01309113 | PHASE3 | COMPLETED | Dose-dependent Effects of VAC BNO 1095 on Cyclic Mastodynia and Premenstrual Syndrome |
| NCT01365676 | PHASE3 | UNKNOWN | GAMALINE®+HIPERICIN® for PMS Treatment and Vasomotor Symptoms |
| NCT01870687 | PHASE3 | TERMINATED | Efficacy and Safety of 20 mg (2 Tablets of 10mg)VAC BNO 1095 FCT on Cyclic Mastodynia and PMS |
| NCT02089620 | PHASE3 | COMPLETED | Comparison Between Oral Contraceptive Pills and Calcium Supplements in Treatment of Premenstrual Syndrome |
| NCT02427334 | PHASE3 | UNKNOWN | Dienogest Versus Luteal Phase Fluoxetine in the Management of Premenstrual Syndrome |
| NCT02488538 | PHASE3 | UNKNOWN | Combined Oral Contraceptives and Fluoxetine Versus Combined Oral Contraceptives in Severe Premenstrual Syndrome |
| NCT02562053 | PHASE3 | UNKNOWN | Does Adding Oral Contraceptives to Fluoxetine Improve the Management of Premenstrual Syndrome? |
| NCT03298607 | PHASE3 | COMPLETED | The Impact of Serelys PMS on Symptoms of PMS |
| NCT06227676 | PHASE2/PHASE3 | COMPLETED | Effect of ‘Cramp Bites’ on Period Cramps in Women Aged 18-25 |
| NCT00048854 | PHASE1/PHASE2 | COMPLETED | Antidepressant Treatment for Premenstrual Syndrome and Premenstrual Dysphoric Disorder |
| NCT00089414 | PHASE2 | TERMINATED | Treatment of Menstrually Related Disorders With Continuous v. Interrupted Oral Contraceptives |
| NCT00672607 | PHASE2 | COMPLETED | a Clinical Trial to Evaluate the Efficacy and Safety of Agnucaston Tablets in the Treatment of Premenstrual Syndrome (PMS) |
| NCT00866437 | PHASE2 | UNKNOWN | Evaluation of Efficacy/Safety of EVE-PMS Skin Test Panel |
| NCT00873262 | PHASE2 | UNKNOWN | Evaluation of Safety/Efficacy of Diagnostic Skin Test Panel and Desensitization Hormone Kit for Treatment of Premenstrual Syndrome (PMS) |
| NCT01782040 | PHASE2 | COMPLETED | Auriculotherapy in the Cares to the Premenstrual Syndrome |
| NCT02100540 | PHASE2 | COMPLETED | A Study to Evaluate the Effects of RCN3028 on Moderate to Severe Vasomotor Symptoms in Women |
| NCT02467088 | PHASE2 | COMPLETED | An Observational Study on the Efficacy of Individualised Homoeopathic Treatment on Premenstrual Syndrome |
| NCT02481973 | PHASE2 | COMPLETED | The Effect of Individualised Homoeopathic Treatment Using the Grant Bentley Method in Premenstrual Syndrome |
| NCT00001259 | PHASE1 | COMPLETED | A Treatment Study for Premenstrual Syndrome (PMS) |
| NCT00082043 | PHASE1 | COMPLETED | Dutasteride to Treat Women With Menstrually Related Mood Disorders |
| NCT05845970 | PHASE1 | COMPLETED | An Investigation Into the Efficacy of a Botanical Supplement to Provide Period Relief |
| NCT03676725 | EARLY_PHASE1 | COMPLETED | Prevalence of Lidocaine Ineffectiveness in Adults With and Without ADHD |
| NCT06370429 | Not specified | NOT_YET_RECRUITING | Effect of Online Exercises for Premenstrual Syndrome on Couple’s Stress and Family Function |
| NCT06621680 | Not specified | NOT_YET_RECRUITING | Effect of Connective Tissue Massage on Premenstrual Syndrome |
| NCT06771583 | Not specified | RECRUITING | Identification and Validation of Epigenetic Biomarkers of PMDD |
| NCT07084714 | Not specified | RECRUITING | Moderate Aerobic Exercise for Managing Menstrual Cycle Symptoms |
| NCT07097181 | Not specified | NOT_YET_RECRUITING | The Effect of Sensory Awareness Education on Female Students’ Body Awareness and Premenstrual Symptom Levels |
| NCT07171814 | Not specified | NOT_YET_RECRUITING | Cohort Study of Honghua Xiaoyao Tablets in the Treatment of Premenstrual Syndrome Based on Target Trial Emulation Framework |
| NCT07189299 | Not specified | NOT_YET_RECRUITING | Microdosing LSD in Women With Premenstrual Disorders |
| NCT07202650 | Not specified | RECRUITING | THE EFFECT OF GUİDED IMAGERY ON PREMENSTRUAL SYNDROME |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| FLUOXETINE | 4 | 12 |
| ETHINYL ESTRADIOL | 4 | 4 |
| LEVONORGESTREL | 4 | 3 |
| DROSPIRENONE | 4 | 2 |
| PAROXETINE | 4 | 2 |
| DIENOGEST | 4 | 1 |
| DUTASTERIDE | 4 | 1 |
| ESCITALOPRAM | 4 | 1 |
| FLUTAMIDE | 4 | 1 |
| SERTRALINE | 4 | 1 |
| LYSERGIDE | 2 | 1 |
| OXALOACETATE | 2 | 1 |
| CHEMBL1074 | 0 | 3 |
| CHEMBL1788361 | 0 | 2 |
| CHEMBL4759307 | 0 | 1 |
| CHEMBL4073387 | 0 | 1 |